ABBV-CLS-484 Clinical Trials (2026): 2 Studies for Advanced Solid Tumor Cancer

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2 ABBV-CLS-484 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Solid Tumor Cancer) and 248 total planned enrollment. 1 ABBV-CLS-484 clinical trial is actively recruiting at 13 U.S. sites across 10 states. Most recent activity: NCT04777994 (Oct 2026).

Where to Participate: All ABBV-CLS-484 Trial Sites in the U.S. (13 sites across 10 states)

Every actively recruiting ABBV-CLS-484trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
AZUniversity of Arizona Cancer Center - Tucson /ID# 262698Tucson85724NCT04777994Map
CTYale University School of Medicine /ID# 225707New Haven06510NCT04777994Map
MDJohns Hopkins Hospital /ID# 254056Baltimore21287NCT04777994Map
MABeth Israel Deaconess Medical Center /ID# 252009Boston02215-5400NCT04777994Map
MADana-Farber Cancer Institute /ID# 249642Boston02215NCT04777994Map
MIUniversity of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 252010Ann Arbor48109NCT04777994Map
NYNYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869New York10016NCT04777994Map
NCDuke Cancer Center /ID# 251975Durham27710NCT04777994Map
PAPerelman Center for Advanced Medicine /ID# 250188Philadelphia19104NCT04777994Map
PAUPMC Hillman Cancer Ctr /ID# 225706Pittsburgh15232NCT04777994Map
RILifespan Cancer Institute at Rhode Island Hospital /ID# 225705Providence02903-4923NCT04777994Map
TXUniversity of Texas Southwestern Medical Center /ID# 251974Dallas75390-7208NCT04777994Map
TXUniversity of Texas MD Anderson Cancer Center /ID# 252004Houston77030NCT04777994Map

ABBV-CLS-484 clinical trials at a glance: phase × recruitment status

PhaserecruitingavailableTotal
P111
N/A11

Recruiting ABBV-CLS-484 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT04777994Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsP1Advanced Solid Tumor Cancer248Mar 2021

All ABBV-CLS-484 trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT04777994Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsP1recruiting248Calico Life Sciences LLCMar 2021
NCT06188975Expanded Access to ABBV-CLS-484available0Calico Life Sciences LLC

ABBV-CLS-484 clinical trials: frequently asked questions

How many ABBV-CLS-484 clinical trials are there?
2 ABBV-CLS-484 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are ABBV-CLS-484 clinical trials recruiting in 2026?
Yes — 1 ABBV-CLS-484 trial is actively recruiting in 2026, with 13 U.S. sites across 10 states. See the recruiting trials and the per-state site list further down this page.
What conditions is ABBV-CLS-484 being studied for?
ABBV-CLS-484 is being studied for Advanced Solid Tumor Cancer. The trials are grouped by indication on this page.
What phase is ABBV-CLS-484 in?
ABBV-CLS-484 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors ABBV-CLS-484 clinical trials?
The lead sponsor across the most ABBV-CLS-484 trials is Calico Life Sciences LLC. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ABBV-CLS-484as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: